Queen's University Belfast-led research reports on a multicenter trial finding no significant reduction in pulmonary ...

Bronchiectasis guidelines are inconsistent with regard to the effectiveness of mucoactive agents, and their use varies ...

Mucoactive agents did little to stave off pulmonary exacerbations of non-cystic fibrosis bronchiectasis, the CLEAR trial ...

United Therapeutics Corporation ( NASDAQ: UTHR) Bernstein 2nd Annual Global Healthcare Conference September 23, 2025 1:10 PM EDT ...

In February 2010, aztreonam for inhalation solution (Cayston; Gilead) — an inhalable formulation of the monobactam antibiotic aztreonam and lysine — was approved by the US FDA to improve respiratory ...

United Therapeutics UTHR remains poised to expand Tyvaso’s label in the respiratory disease space. It recently unveiled results from the late-stage TETON-2 study, which showed clinical benefit in ...

The global smart inhalers market size was US$ 147.7 million in 2021. The global smart inhalers market size is forecast to reach US$ 1,116.5 million by 2030, growing at a compound annual growth rate ...

In Villanueva, Misamis Oriental — where two coal-fired power plants dominate the skyline — residents live with health worries they've grown almost accustomed to. Many have accepted the trade-off, ...

Newman University experts identify key qualities of exceptional respiratory therapists: technical skills, calm under pressure ...

Zookeepers spent three years teaching 16-year-old Mahiri how to confidently use an inhaler, which Banham Zoo designed to ...

A new Northwestern Medicine study is challenging long-held assumptions about chronic obstructive pulmonary disease (COPD), ...

Biological therapy was associated with significant changes in lung structure and, by extension, improved lung function in ...